Stockreport

Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans [Yahoo! Finance]

Mineralys Therapeutics, Inc.  (MLYS) 
PDF reductions in blood pressure and albuminuria among patients with chronic kidney disease and hypertension. The company announced plans to file a New Drug Application wi [Read more]